Methods and systems for generating nanoparticles
In one aspect, the present invention provides a process for forming polymeric nanoparticles, which comprises using a static mixer to create a mixed flowing stream of an anti-solvent, e.g., by introducing a liquid anti-solvent into a static mixer, and introducing a polymer solution into the mixed flowing anti-solvent stream such that controlled precipitation of polymeric nanoparticles occurs. The nanoparticles can then be separated from the anti-solvent stream.
1. A population of polymeric nanoparticles, comprising:
a plurality of polymeric nanoparticles having an amphiphilic co-polymer as at least one constituent, wherein said amphiphilic co-polymer includes polylactic acid (PLA) as one of its polymeric components,
wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 100 nm and a polydispersity index in a range of about 0.05 and about 0.1.
2. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 95 nm.
3. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 90 nm.
4. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 85 nm.
5. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 80 nm.
6. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 75 nm.
7. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 70 nm.
8. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 65 nm.
9. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 60 nm.
10. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 55 nm.
11. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 50 nm.
12. The population of the polymeric nanoparticles of claim 1 , wherein said polymeric nanoparticles comprise any of a therapeutic agent or an imaging agent.
13. The population of the polymeric nanoparticles of claim 12 , wherein said therapeutic agent is any of a taxane, an epothilone, a boronic acid proteasome inhibitor, and an anti-biotic.
14. The population of the polymeric nanoparticles of claim 12 , wherein said therapeutic agent is an anti-neoplastic agent.
15. The population of the polymeric nanoparticles of claim 14 , wherein said anti-neoplastic agent is a taxane.
16. The population of the polymeric nanoparticles of claim 15 , wherein said taxane is any of paclitaxel, docetaxel, larotaxel and cabazitaxel.
17. The population of the polymeric nanoparticles of claim 1 , wherein said population includes at least about 10 grams of said nanoparticles.
18. The population of the polymeric nanoparticles of claim 1 , wherein said population includes at least about 50 grams of said nanoparticles.
19. The population of the polymeric nanoparticles of claim 1 , wherein said population includes at least about 100 grams of said nanoparticles.
20. The population of the polymeric nanoparticles of claim 1 , wherein said population includes at least about 500 grams of said nanoparticles.
21. The population of the polymeric nanoparticles of claim 1 , wherein said population comprises a lyoprotectant.
22. A population of polymeric nanoparticles, comprising:
a plurality of polymeric nanoparticles having an amphiphilic co-polymer as at least one constituent, wherein said amphiphilic co-polymer includes polyglycolic acid (PGA) as one of its polymeric components,
wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 100 nm and a polydispersity index in a range of about 0.05 and about 0.1.
23. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 95 nm.
24. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 90 nm.
25. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 85 nm.
26. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 80 nm.
27. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 75 nm.
28. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 70 nm.
29. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 65 nm.
30. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 60 nm.
31. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 55 nm.
32. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles exhibit an average particle size equal to or less than about 50 nm.
33. The population of the polymeric nanoparticles of claim 22 , wherein said polymeric nanoparticles comprise any of a therapeutic agent or an imaging agent.
34. The population of the polymeric nanoparticles of claim 22 , wherein said therapeutic agent is any of a taxane, an epothilone, a boronic acid proteasome inhibitor, and an anti-biotic.
35. The population of the polymeric nanoparticles of claim 32 , wherein said therapeutic agent is an anti-neoplastic agent.
36. The population of the polymeric nanoparticles of claim 33 , wherein said anti-neoplastic agent is a taxane.
37. The population of the polymeric nanoparticles of claim 34 , wherein said taxane is any of paclitaxel, docetaxel, larotaxel and cabazitaxel.
38. The population of the polymeric nanoparticles of claim 22 , wherein said population includes at least about 10 grams of said nanoparticles.
39. The population of the polymeric nanoparticles of claim 22 , wherein said population includes at least about 50 grams of said nanoparticles.
40. The population of the polymeric nanoparticles of claim 22 , wherein said population includes at least about 100 grams of said nanoparticles.
41. The population of the polymeric nanoparticles of claim 22 , wherein said population includes at least about 500 grams of said nanoparticles.
42. The population of the polymeric nanoparticles of claim 22 , wherein said population comprises a lyoprotectant.